Physician profile
Douglas Ginas
NPI 1629059456
$5,535.61
in general payments reported to CMS, 2019-2025
40 companies · $993 in 2025
The $993 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $786 · 2021: $1,123 · 2022: $820 · 2023: $732 · 2024: $759 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,433.80 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,062.72 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Gilead Sciences, INC. | $350.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $282.25 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $280.22 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Allergan, INC. | $226.67 | 2020 | |
| Indivior INC. | $200.03 | 2019-2025 | Sublocade |
| Pfizer INC. | $190.56 | 2020-2025 | |
| Novo Nordisk INC | $161.42 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Orexo US, INC. | $136.07 | 2019-2024 | Zubsolv |
| Eisai INC. | $125.96 | 2020-2022 | |
| Exact Sciences Corporation | $103.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $80.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $73.98 | 2019-2022 | |
| Lilly USA, LLC | $72.96 | 2020-2024 | Jardiance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Ginas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.